Altimmune (NASDAQ: ALT) is a late clinical-stage biopharmaceutical company focused on developing innovative therapies for patients suffering from serious liver diseases. The company's lead candidate, pemvidutide, is a unique dual-action therapy designed to target both glucagon and GLP-1 receptors, aimed at treating metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). Altimmune is committed to advancing clinical development through rigorous statistical strategies and high-quality data management, ensuring the scientific integrity of its clinical trials and regulatory submissions.